Eligibility for Semaglutide 2.4 mg in US Adults with Obesity and Prediabetes, Based on the STEP-10 Trial Criteria
Chetty A, Khunte M, Lu Y, Chen A. Eligibility for Semaglutide 2.4 mg in US Adults with Obesity and Prediabetes, Based on the STEP-10 Trial Criteria. American Heart Journal 2024, 278: 10. DOI: 10.1016/j.ahj.2024.09.026.Peer-Reviewed Original ResearchUS populationNational Health and Nutrition Examination SurveyHealth and Nutrition Examination SurveyPrevention of type 2 diabetesUnder-representation of malesNutrition Examination SurveyPeople of BlackExamination SurveyWaist circumferenceUS adultsHispanic race/ethnicityType 2 diabetesAnti-obesity medicationsDocumented BMIReversion to normoglycemiaStudy sampleNon-medicalWhite raceObesityPrediabetesAdultsBMIMean body weightParticipantsHbA1c